70770-03-5

Basic information

• Product Name: 4-(3,4-dimethoxyphenyl)-4-oxobutanenitrile
• Synonyms: 4-(3,4-dimethoxyphenyl)-4-oxobutanenitrile
• CAS NO: 70770-03-5
• Molecular Weight: 219.24
• Mol File: 70770-03-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(3,4-dimethoxyphenyl)-4-oxobutanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-dimethoxyphenyl)-4-oxobutanenitrile(70770-03-5)
• EPA Substance Registry System: 4-(3,4-dimethoxyphenyl)-4-oxobutanenitrile(70770-03-5)

Safety Data

• Hazardous Substances Data: 70770-03-5(Hazardous Substances Data)

Upstream product

• 4568-71-2 3-benzyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 107-13-1 acrylonitrile 
• 1239346-64-5 4-(3,4-dimethoxyphenyl)-4-nitrobutanenitrile 
• 143-33-9 sodium cyanide 
• 151-50-8 potassium cyanide 

Downstream Products

• 5333-34-6 3-(3,4-dimethoxybenzoyl)propionic acid 
• 367281-00-3 2-(3,4-dimethoxyphenyl)pyrrolidine 
• 91640-98-1 5-(3,4-dimethoxyphenyl)-3,4-dihydro-2H-pyrrole 

Relevant articles and documents

KMnO4-mediated oxidation as a continuous flow process

An efficient and easily scalable transformation of alcohols and aldehydes to carboxylic acids and nitroalkane derivatives to the corresponding carbonyls and carboxylic acids using permanganate as the oxidant within a continuous flow reactor is reported. Notably, the generation and downstream processing of MnO2 slurries was not found to cause any blocking of the reactor when ultrasound pulses were applied to the flow system.

COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS

Enantiomerically enriched disubstituted tetrahydrofurans, tetrahydrothiophenes, pyrrolidines and cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. It has been determined that 5-lipoxygenase activity, oral availability, and stability in vivo (for example, glucuronidation rate) can vary significantly among the optical isomers of the disclosed compounds.